CURIGLIANO, GIUSEPPE
CURIGLIANO, GIUSEPPE
Dipartimento di Oncologia ed Emato-Oncologia
Publisher Correction: APOBEC3 mutagenesis drives therapy resistance in breast cancer
2026 A. Gupta, A. Gazzo, P. Selenica, A. Safonov, F. Pareja, E.M. Da Silva, D.N. Brown, H. Shao, Y. Zhu, J. Patel, J. Blanco-Heredia, B. Stefanovska, M.A. Carpenter, Y. Chen, I. Vegas, X. Pei, D. Frosina, A.A. Jungbluth, M. Ladanyi, G. Curigliano, B. Weigelt, N. Riaz, S.N. Powell, P. Razavi, R.S. Harris, J.S. Reis-Filho, A. Marra, S. Chandarlapaty
Corrigendum to: "Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis" [Eur J Cancer 145 (2021) 197-209]
2026 A. Esposito, A. Marra, V. Bagnardi, S. Frassoni, S. Morganti, G. Viale, P. Zagami, G.M. Varano, G. Buccimazza, F. Orsi, K. Venetis, L. Mazzarella, G. Viale, N. Fusco, C. Criscitiello, G. Curigliano
Clinical characteristics and drug-drug interactions in human epidermal growth factor receptor 2-positive breast cancer treated with trastuzumab deruxtecan: real-world data from the DE-REAL study
2026 S. Pisegna, S. Scagnoli, G. Gentile, A. Chiavassa, R. Caputo, M. De Laurentiis, G. Curigliano, M. Lambertini, F. Pantano, A. Orlandi, A. Palazzo, I. Paris, C. Vernieri, B. Tedesco, M. Giampaglia, M. Palleschi, Z. Ballatore, D. Alesini, G. D'Auria, M.A. Fabbri, L. Rossi, G. Fiscon, P. Marchetti, A. Fabi, A. Botticelli
Clinical and translational results from the phase II ABACO trial evaluating the activity of cabozantinib in pretreated patients with metastatic colorectal cancer
2026 V. De Falco, P.P. Vitiello, D. Ciardiello, G. Grasso, E. Mariella, G. Martini, S. Napolitano, C. Cardone, G. Arrichiello, E. Varriale, M. Di Bisceglie, T. Latiano, E. Maiello, A. Reginelli, M.C. Brunese, S. Cappabianca, S. Del Tufo, A. Orlando, A. Nicastro, F. Caraglia, L. Esposito, D. Renato, A. Avallone, M. Orditura, N. Fazio, G. Curigliano, M.G. Zampino, A. Bardelli, F. Ciardiello, T. Troiani, E. Martinelli
The role of the molecular tumor board: learnings from the ROME trial
2026 P. Marchetti, G. Curigliano, C.B. Westphalen, M. Biffoni, S. Lonardi, S. Scagnoli, L. Fornaro, V. Guarneri, U. De Giorgi, P.A. Ascierto, G. Blandino, G. D'Amati, M. Aglietta, C. Cremolini, P. Conte, E. Crimini, M. Ceracchi, S. Pisegna, S. Verkhovskaia, R. Bordonaro, S. Bracarda, G. Butturini, L. Del Mastro, A. Decensi, A. Fabbri, F. De Galitiis, E. Fenocchio, S. Gori, G. Metro, A. Pessino, D. Pozzessere, F. Puglisi, S. Tamberi, A. Zambelli, D. Marino, E. Capoluongo, F. Cappuzzo, B. Cerbelli, G. Giannini, U. Malapelle, F. Mazzuca, M. Nuti, G. Pruneri, M. Simmaco, L. Strigari, G. Tonini, A. Savarese, V. Adamo, D. Quaresmini, P. Tagliaferri, P. Damiano, B. Urbini, C. Bengala, E. Zaffignani, C. Pinto, A. Tosoni, L. Buffoni, E. Maiello, C. Mucciarini, A. Russo, R. Berardi, G. Lombardi, A. Piancastelli, G. Masi, L. Bonanno, V. Vanella, F. Mannozzi, N. Martini, A. Botticelli
Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03
2026 C. Saura, J. Cortés, S. Modi, S. Kim, E. Hamilton, S.A. Hurvitz, I.E. Krop, G. Curigliano, H. Iwata, S. Im, P. Herbolsheimer, M. Karnoub, A. Boran, Y. Kuwahara, A. Egorov, F. André
A machine learning assay to predict disease recurrence in hormone receptor-positive breast cancer
2026 L. Boscolo Bielo, D. Trapani, P. Razavi, S. Chandarlapaty, Y. Zhan, G. Curigliano
Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non-Small Cell Lung Cancer: Results From CHRYSALIS-2
2026 P. Tomasini, Y. Wang, Y. Li, E. Felip, L. Wu, J. Cui, B. Besse, A.I. Spira, J.W. Neal, K. Goto, C.S. Baik, M.E. Marmarelis, G. Curigliano, E. Ichihara, Y. Zhang, J. Lee, S. Lee, J.C. Yang, S. Michels, Z. Anastasiou, J.C. Curtin, X. Lyu, J. Mahoney, L. Demirdjian, C.S. Meyer, Y. Zhang, I. Leconte, P. Lorenzini, R.E. Knoblauch, L. Trani, M. Baig, J.M. Bauml, B.C. Cho
Sequential Use of Trastuzumab Deruxtecan and Sacituzumab Govitecan in Patients with Breast Cancer: A Pharmacological Approach to Support the Clinical Rationale
2026 M. Del Re, E. Inglese, E. Bria, E.J. Blok, R.H.J. Mathijssen, G. Curigliano, R. Danesi
Including tumor-infiltrating lymphocytes into the PREDICT prognostic model for triple-negative breast cancer survival
2026 Y. Wang, D. Drubay, S.F. Jonas, J. Dixon-Douglas, B. Acs, S. Adams, F. André, S. Badve, G. Bataillon, J.M. Carter, S. Chia, V. Cockenpot, M.A. Colleoni, C. Criscitiello, G. Curigliano, G.M.H.E. Dackus, S. Demaria, C. Denkert, C.H.M. Van Deurzen, M.V. Dieci, D. Giardiello, M.P. Goetz, R.J. Gray, M. Hauptmann, N.D.T. Hoeve, K. Jóźwiak, E.A. Koop, V.M.T. De Jong, H. Joensuu, G. Jules-Clément, R. Kammler, P.L. Kellokumpu-Lehtinen, S.B. Kim, M. Kok, M. Lacroix-Triki, M. Lambertini, H.J. Lee, J. Lemonnier, R.A. Leon-Ferre, S. Leung, B. Linderholm, S. Loibl, J.W.M. Martens, T.O. Nielsen, M. Opdam, P. Pharoah, F. Penault-Llorca, M. Piccart, L. Pustzai, N. Riaz, A. Vincent-Salomon, J. Sparano, T. Shimoi, C. Sotiriou, V.J. Suman, A.M. Timmermans, P.J. Van Diest, A.C. Voogd, G. Viale, A.C. Wolff, S. Yazaki, M. Yoshida, R. Salgado, S.C. Linn, M.K. Schmidt, S. Loi, S. Michiels
Impact of breast cancer on sexuality and psycho-physical wellbeing: Survey analysis
2026 P. Zagami, B.T. Salimbeni, E.P. Preti, A. Esposito, A. Marra, D. Trapani, E. Munzone, M. Mazza, S. Martella, I. Durosini, S. Perazzo, R. Marsicano, P.P. Maria Berton Giachetti, G. Curigliano, C. Criscitiello, G. Pravettoni
Clinical management of common toxicities with inhibitors targeting the PI3K/AKT/mTOR pathway in breast cancer
2026 K.L. Jhaveri, N.M. Iyengar, N.C. Turner, H.S. Rugo, J. O'Shaughnessy, C.H. Barrios, G. Curigliano, F. André, S. Im, M.D. Goncalves, M.E. Lacouture, P.A. Fasching, R. Leung
Enhancing Clinical Cancer Research Through Sharing of Data and Biospecimens
2026 H. Wildiers, V. Adam, S. O'Reilly, J. Van Cauwenberge, A. Arahmani, C.L. Arteaga, P.L. Bedard, J. Bliss, P. Boussis, E. Brain, M. Buyse, C. Caballero, D. Cameron, F. Cardoso, E. Carrasco, A. Casas, B. Chua, G. Curigliano, A. Demichele, L. Esserman, G. Floris, M.P. Goetz, T. Goulioti, B. Haibe-Kains, C. Hodgdon, M. Ignatiadis, M. Kok, D. Lacombe, B. Linderholm, S. Loi, C.J. Lord, M. Mackenzie, J. Maues, L. Meheus, J. Needham, P. Neven, H. Parsons, M. Piccart, L. Pusztai, E. Razis, S. Saji, E. Schumacher-Wulf, G.S. Sonke, T. Spanic, I.F. Tannock, A. Tutt, A. Urruticoechea, L. Van 'T Veer, I. Vaz-Luis, G. Werutsky, D. Yee, K. Zaman, C. Desmedt
Pathological complete response with neoadjuvant pembrolizumab and chemotherapy in non-metastatic triple-negative inflammatory breast cancer
2026 F. Lynce, C. Valenza, S.M. Niman, F. Bertucci, M. Kai, S. Ryan, E. Troll, R.M. Layman, K.A. Fanucci, A. Giordano, A. Nasrazadani, F. Nakhlis, J. Bellon, L. Warren, C. Block, S. Schumer, A. Lucci, S. Krishnamurthy, D. Trapani, F. Lerebours, F. Dalenc, C. Levy, T. Petit, M. Leheurteur, T. Bachelot, O. Tredan, J.M. Ribeiro, B. Pistilli, P. Zagami, S. Ladoire, L. Lopez Almeida, C. Zemmour, L.A. Carey, S.M. Tolaney, V. Valero, G. Curigliano, M.M. Regan, A. Goncalves, W.A. Woodward
Molecular and Clinical Analyses of Gene Fusions Identify Therapeutic Targets in Paired Primary and Metastatic Breast Cancer from the AURORA Program (BIG 14-01)
2026 C. Biagioni, D. Fimereli, A. Irrthum, A. Guerrero-Zotano, M. Piccart, D. Cameron, C. Caballero, A. Raimbault, D. Martins-Branco, D. Romagnoli, E. Agostinetto, D. Venet, A. Llinas-Bertran, J.A. Seoane, G. Zoppoli, A. Vivancos, A. Vingiani, M. Oliveira, G. Curigliano, T. Crestani, C. Sotiriou, E. Nili Gal-Yam, F.S. Hilbers, P. Aftimos, M. Benelli
Genomic landscape, immune microenvironment and survival in male versus female breast cancer
2026 D. Trapani, S.K. Deshmukh, T. Samec, S. Wu, J. Xiu, P. Walker, D.L. Abravanel, P. Advani, P.M. Spanheimer, N.U. Lin, G. Curigliano, S.L. Graff, M. Lustberg, G.W. Sledge, S.M. Tolaney, J.P. Leone
Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer
2026 P. Tarantino, S. Kim, M.E. Hughes, R.J. Kusmick, K. Smith, F. Brasó-Maristany, N.N. Nyein Chan, L. Paré Brunet, L. Alder, D. Garcia-Cortes, J. Gomez Tejeda Zanudo, A.M. Pereslete, L. Noteware, H. Moore, A.E.D. Van Swearingen, T. Li, H. Gupta, O. D'Amico, A. Martini, S. Morganti, J. Spindel, C. Cook, C. Mclaughlin, K. Dvir, A.C. Garrido-Castro, S. Sammons, J. Files, K. Sendrick, S. Buck, D. Dillon, R. Jeselsohn, Y.Y. Li, A.D. Cherniack, P. Lorusso, M. Lustberg, R. Vega-León, F. Pardo, J. Davis, C. Mueller, B. Corgiat, G. Curigliano, C.K. Anders, E.F. Petricoin, D.L. Rimm, A. Prat, N. Tayob, N.U. Lin, S.M. Tolaney
Impact of whole breast irradiation, endocrine therapy or their combination on outcomes of early-stage, luminal A-like, low-risk, breast cancer patients aged 65 years or over: Insights from the EUSOMA database
2026 C. Aristei, M. Tomatis, A. Ponti, L. Marotti, N.M.L. Battisti, K. Leung Cheung, O.J. Hartmann, I.T. Rubio, D. Santini, F. Sardanelli, E. Senkus, P. Van Dam, G. Curigliano
Cetuximab rechallenge in molecularly selected metastatic colorectal cancer: the randomized CAVE-2 GOIM trial
2026 D. Ciardiello, G. Martini, L. Boscolo Bielo, F. Pietrantonio, A. Raimondi, P. Manca, S. Pisconti, C. Nisi, G. Tortora, L. Salvatore, A. Sartore-Bianchi, S. Siena, L. Blasi, E. Ongaro, A. Zaniboni, C. Pinto, L. Antonuzzo, A. Avallone, N. Normanno, G. Santabarbara, M.G. Zampino, R. Berardi, A. Cogoni, C. Lotesoriere, T.P. Latiano, E. Maiello, N. Fazio, G. Curigliano, R. Bordonaro, T. Troiani, F. De Vita, E. Martinelli, F. Ciardiello, S. Napolitano
Scientific highlights and perspectives from the International Inflammatory Breast Cancer Symposium 2025
2026 E. Nicolò, F. Bertucci, H. Boussen, G. Curigliano, V. Fraser, L. Gerratana, S. Krishnamurthy, H.T. Le‐petross, B. Lim, F. Lynce, A. Lucci, S. Lucotti, M. Manai, S. Merajver, N. Missal, A. Nasrazadani, A. Soliman, C. Valenza, C. Van Berckelaer, S. Van Laere, W.A. Woodward, M. Cristofanilli, G. Devi